Change in speaking fundamental frequency in hormone-treated patients with Turner's syndrome--a longitudinal study of four cases.
Change in speaking fundamental frequency for four hormone-treated girls with Turner's syndrome was registered using two computerized analysis methods for a period of four years. The girls were treated with human growth hormone, oxandrolone and ethinyl estradiol. The overall pattern for three of the girls was a distinct decline in speaking fundamental frequency during the first year, while for the fourth patient the pattern of change was more complicated. For all four girls, the final pitch level was within the normal range for adult women. It is important that voice effects are taken into account in the hormonal treatment of Turner's syndrome and that patients are informed of the changes to be expected.
Andersson-Wallgren
G
G
Department of Logopedics and Phoniatrics, University of Göteborg, Sweden.
Albertsson-Wikland
K
K
D000293:Adolescent; D002648:Child; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D008137:Longitudinal Studies; D010074:Oxandrolone / Q000008:administration & dosage*; D014424:Turner Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D014833:Voice Quality / Q000187:drug effects*
D004997:Ethinyl Estradiol; D010074:Oxandrolone; D013006:Growth Hormone